دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation.
Vokes, Everett E. MD, FASCO 1,2,,
doi : 10.1200/JCO.22.01305
Volume 40(25) pgs. 2859-3002 September 1, 2022
Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!
Landgren, Ola MD, PhD 1,,; Kazandjian, Dickran MD 1,
doi : 10.1200/JCO.22.00622
Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma.
Voss, Martin H. MD 1,,
doi : 10.1200/JCO.22.00834
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.
Passaro, Antonio MD, PhD 1,,; Attili, Ilaria MD 1; de Marinis, Filippo MD 1,
doi : 10.1200/JCO.22.00873
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
Rossini, Daniele MD 1,2,; Antoniotti, Carlotta MD, PhD 1,2; Lonardi, Sara MD 3,; Pietrantonio, Filippo MD 4,; Moretto, Roberto MD 2; Antonuzzo, Lorenzo MD, PhD 5; Boccaccino, Alessandra MD 1,2; Morano, Federica MD 4,; Brugia, Marco MD 6; Pozzo, Carmelo MD 7,; Marmorino, Federica MD, PhD 1,2; Bergamo, Francesca MD 8; Tamburini, Emiliano MD 9; Passardi, Alessandro MD 10; Randon, Giovanni MD 4; Murgioni, Sabina MD 8; Borelli, Beatrice MD 1,2; Buonadonna, Angela MD 11; Giordano, Mirella PhD 1,2; Fontanini, Gabriella MD, PhD 12; Conca, Veronica MD 1,2; Formica, Vincenzo MD, PhD 13,; Aglietta, Massimo MD 14,; Bordonaro, Roberto MD 15,; Aprile, Giuseppe MD 16,; Masi, Gianluca MD 1,2; Boni, Luca MD 17,; Cremolini, Chiara MD, PhD 1,2,,
doi : 10.1200/JCO.22.00839
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute, Ruth M. PhD 1,; Pawlyn, Charlotte MBBChir, PhD 2,3,; Cairns, David A. PhD 4,; Davies, Faith E. MBBCh, MD 5,; Menzies, Tom MSc 4,; Rawstron, Andy PhD 1,; Jones, John R. MD, PhD 6,7,8,; Hockaday, Anna BSc 4,; Henderson, Rowena MSc 4,; Cook, Gordon MD, PhD 4,9,; Drayson, Mark T. MD, PhD 10,; Jenner, Matthew W. MD 11,; Kaiser, Martin F. MD 2,3,; Gregory, Walter M. PhD 4,; Morgan, Gareth J. MD, PhD 5,; Jackson, Graham H. MD, PhD 12,; Owen, Roger G. MBBCh, MD 1,,
doi : 10.1200/JCO.21.02228
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa, Luciano J. MD, PhD 1,2,,; Chhabra, Saurabh MD 3,; Medvedova, Eva MD 4; Dholaria, Bhagirathbhai R. MD 5,; Schmidt, Timothy M. MD 6,; Godby, Kelly N. MD 1,2; Silbermann, Rebecca MD 4,; Dhakal, Binod MD 3,; Bal, Susan MD 1,2,; Giri, Smith MD 1,2,; D'Souza, Anita MD 3,; Hall, Aric MD 6; Hardwick, Pamela RN 2; Omel, James MD 7,; Cornell, Robert F. MD 5,; Hari, Parameswaran MD 3,; Callander, Natalie S. MD 6
doi : 10.1200/JCO.21.01935
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Atkins, Michael B. MD 1,,; Jegede, Opeyemi A. MPH 2; Haas, Naomi B. MD 3,; McDermott, David F. MD 4,; Bilen, Mehmet A. MD 5,; Stein, Mark MD 6,; Sosman, Jeffrey A. MD 7,; Alter, Robert MD 8; Plimack, Elizabeth R. MD 9,; Ornstein, Moshe MD 10,; Hurwitz, Michael MD 11,; Peace, David J. MD 12,; Signoretti, Sabina MD 13,; Denize, Thomas BA 13; Cimadamore, Alessia BA 13,; Wu, Catherine J. MD 2,; Braun, David MD, PhD 11,; Einstein, David MD 4,; Catalano, Paul J. ScD 2,; Hammers, Hans MD, PhD 14,
doi : 10.1200/JCO.21.02938
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
Provencio, Mariano MD, PhD 1,,; Serna-Blasco, Roberto MSc 1; Nadal, Ernest MD 2,; Insa, Amelia MD 3,; Garcia-Campelo, M. Rosario MD 4,; Casal Rubio, Joaquin MD 5; Domine, Manuel MD 6,; Majem, Margarita MD 7,; Rodriguez-Abreu, Delvys MD 8,; Martinez-Marti, Alex MD 9,; De Castro Carpeno, Javier MD 10,; Cobo, Manuel MD 11; Lopez Vivanco, Guillermo MD 12; Del Barco, Edel MD 13,; Bernabe Caro, Reyes MD 14; Vinolas, Nuria MD 15,; Barneto Aranda, Isidoro MD 16; Viteri, Santiago MD 17,; Pereira, Eva MSc 18; Royuela, Ana PhD 1; Calvo, Virginia MD 1,; Martin-Lopez, Javier MD 1,; Garcia-Garcia, Francisco PhD 19; Casarrubios, Marta MSc 1; Franco, Fernando MD 1; Sanchez-Herrero, Estela MSc 1,20; Massuti, Bartomeu MD 21,; Cruz-Bermudez, Alberto PhD 1; Romero, Atocha PhD 1,
doi : 10.1200/JCO.21.02660
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Vliek, Sonja B. MD 1; Noordhoek, Iris BSc 2,3; Meershoek-Klein Kranenbarg, Elma MSc 3; van Rossum, Annelot G.J. MD, PhD 1; Dezentje, Vincent O. MD, PhD 1,; Jager, Agnes MD, PhD 4; Hokken, J.W. Esmeralda MD, PhD 5; Putter, Hein PhD 6; van der Velden, Annette W.G. MD, PhD 7; Hendriks, Mathijs P. MD, PhD 8,; Bakker, Sandra D. MD, PhD 9; van Riet, Yvonne E.A. MD, PhD 10; Tjan-Heijnen, Vivianne C.G. MD, PhD 11,; Portielje, Johanneke E.A. MD, PhD 2; Kroep, Judith R. MD, PhD 2,; Nortier, Johan W.R. MD, PhD 2; van de Velde, Cornelis J.H. MD, PhD 3; Linn, Sabine C. MD, PhD 1,12,,
doi : 10.1200/JCO.21.00311
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Huober, Jens MD 1,2,,; Barrios, Carlos H. MD 3,; Niikura, Naoki MD, PhD 4,; Jarzab, Michal MD, PhD 5,; Chang, Yuan-Ching MD, PhD 6,; Huggins-Puhalla, Shannon L. MD 7,; Pedrini, Jose MD, PhD 8,; Zhukova, Lyudmila MD, PhD 9,; Graupner, Vilma PhD 10,; Eiger, Daniel MD 10,; Henschel, Volkmar PhD 11,; Gochitashvili, Nino MD, PhD 12,; Lambertini, Chiara PhD 13,; Restuccia, Eleonora MD 10,; Zhang, Hong MD, PhD 14,; the IMpassion050 Trial Investigators
doi : 10.1200/JCO.21.02772
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell, W. Kimryn MD, PhD 1,; Rumble, R. Bryan MSc 2; Van Veldhuizen, Peter J. MD 3; Al-Ahmadie, Hikmat MD 4,; Emamekhoo, Hamid MD 5,; Hauke, Ralph J. MD 6,; Louie, Alexander V. MD, MSc, PhD 7,8,; Milowsky, Matthew I. MD 9,; Molina, Ana M. MD 10,; Rose, Tracy L. MD, MPH 9,; Siva, Shankar MD, PhD 11,; Zaorsky, Nicholas G. MD, MS 8,12; Zhang, Tian MD 13,; Qamar, Rubina MD 14; Kungel, Terry M. MBA 15; Lewis, Bryan JD 16,17,; Singer, Eric A. MD, MA, MS 18,
doi : 10.1200/JCO.22.00868
Volume-Based Versus Mortality-Based Standards for Surgical Quality: Both Risk Adjustment and Volume Matter.
Saraswathula, Anirudh MD, MS; Austin, J. Matthew PhD, MS; Fakhry, Carole MD, MPH; Eisele, David W. MD; Kachalia, Allen MD, JD; Gourin, Christine G. MD, MPH
doi : 10.1200/JCO.22.00407
Volume-Based Centralization of Complex Cancer Operations: We Need More Than an Alternate Centralization Strategy.
Fong, Zhi Ven MD, MPH; Traeger, Lara N. PhD; Chang, David C. PhD, MPH, MBA
doi : 10.1200/JCO.22.00242
Reply to A. Saraswathula et al and Z.V. Fong et al.
Baum, Philip MD; Lenzi, Jacopo PhD; Taber, Samantha MD; Winter, Hauke MD; Wiegering, Armin MD
doi : 10.1200/JCO.22.00606
Considerations of Subgroup Classification When Analyzing Risk of Developing Cardiometabolic Risk Factors in Patients With Breast Cancer.
Chen, Ying-Ju MS; Yeh, Ming-Hsin MD, PhD; Wei, James Cheng-Chung MD, PhD
doi : 10.1200/JCO.22.00416
